Immix Biopharma

Immix Biopharma reported a 75% complete response rate in 16 relapsed/refractory AL Amyloidosis patients treated with CAR-T NXC-201, with the best response duration ongoing at 31.5 months. The data, presented at ASH 2024, showed no neurotoxicity and a median CRS duration of 2 days. NXC-201 is under evaluation in U.S. Phase 1b/2 trials, aiming to address the unmet need in AL Amyloidosis treatment.

Immix Biopharma presented new NXC-201 NEXICART-1 clinical data at ASH 2024, showing a 94% overall response rate and 75% complete response rate in relapsed/refractory AL Amyloidosis patients. The study included 16 patients, with no immune effector cell-associated neurotoxicity syndrome events reported.

Immix Biopharma announced Phase 1/2 data for CAR-T therapy NXC-201, showing a 75% complete response rate in relapsed/refractory AL Amyloidosis patients. The therapy demonstrated a 94% overall response rate and 62% organ response rate, with no ICANS cases. Despite a -63% YTD return, analysts suggest potential upside from the current $2.33 trading price.

Immix Biopharma, Inc. will update on CAR-T NXC-201's progress in treating relapsed/refractory AL Amyloidosis in a Dec. 10, 2024, conference call. NXC-201, a CAR-T cell therapy, shows promise with no neurotoxicity and potential expansion into immune-mediated diseases. AL Amyloidosis, a condition with high mortality, affects an estimated 33,277 patients in the U.S. in 2024.

The article discusses the importance of enabling JavaScript for optimal app performance.

Immix Biopharma announced NXC-201, a CAR-T therapy for relapsed/refractory AL Amyloidosis, showing a 75% response rate in patients with a median of 4 prior therapies. Data will be presented at the 66th ASH Annual Meeting in San Diego, December 2024.

Immix Biopharma announced positive NXC-201 clinical data at the 66th ASH Annual Meeting, showing a 75% complete response rate in relapsed/refractory AL Amyloidosis patients. NXC-201, a CAR-T therapy, demonstrated promising results with no neurotoxicity, supporting its development for AL Amyloidosis and potentially other immune-mediated diseases.

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report highlights 75+ companies developing 80+ therapies, including promising candidates like GA Depot, Remibrutinib, and IMU 838. Key events include Immunic's positive Phase 3 ENSURE trial interim analysis, Roche's FDA approval for Ocrevus injectable, and Sanofi's mixed results for tolebrutinib in Phase III trials. The report covers global pipeline stages, product types, molecule types, mechanisms of action, and routes of administration.

Cell and gene therapy sectors see significant progress, including Estrella Immunopharma's EB103 achieving complete response in B-cell lymphomas, NEXICART-2 trial moving to expansion cohort, Ultragenyx planning higher dose evaluation for UX701, Anixa Biosciences seeking FDA approval for second doses of FSHR-targeting CER T-cell therapy, Aspen Neuroscience collaborating with Cell X Technologies for iPSC automation, GEMMABio receiving $100 million from Fiocruz for accessible gene therapy research, MiNK Therapeutics partnering with Autonomous Therapeutics for metastatic tumor treatments, and BioHub Maryland receiving a $75,000 grant for bioprocessing training.

The NEXICART-2 trial evaluating NXC-201 CAR-T therapy for r/r AL amyloidosis has moved to its expansion cohort, using a dose of 450 million CAR+T cells. The trial's primary endpoints are the complete response rate and overall response rate, with Memorial Sloan Kettering Cancer Center as the lead site. Positive data from the NEXICART-1 trial showed a 92% overall response rate and a 28.0-month duration of response.